# Identification of IGF2BP3 and CENPA as key regulators of immunophenotypes in renal clear cell carcinoma

## TL;DR

This study identifies IGF2BP3 and CENPA as key genes linked to immune responses and prognosis in kidney cancer.

## Contribution

The study introduces a novel multigene signature involving IGF2BP3 and CENPA for predicting KIRC prognosis and immune infiltration.

## Key findings

- IGF2BP3 and CENPA are strongly associated with immune cell infiltration in KIRC.
- Silencing CENPA disrupts mitochondrial function and reduces cancer cell viability.
- A multigene signature based on these genes stratifies KIRC patients into distinct risk groups.

## Abstract

Kidney renal clear cell carcinoma (KIRC) is the most common subtype of Renal cell carcinoma (RCC), with a high degree of immune infiltration. This study aimed to identify m6A-related biomarkers and downstream effectors in KIRC that may affect tumor immunity and to provide prognosis biomarkers of KIRC.

In this study, the mRNA expression profiles and corresponding clinical data of KIRC patients were downloaded from The Cancer Genome Atlas (TCGA) to screen out transcription factors and m6A-related genes that were upregulated and unfavorable to the prognosis of KIRC. The multigene signature was constructed using LASSO analysis to selected two transcription factors and a m6A-associated gene, and TCGA cohort was constructed to stratify patients into two risk groups.

Functional analysis showed that immune-related pathways were enriched and that immune status was different between the two risk groups, with Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) and centromere protein A (CENPA) genes highly correlated with immune cell infiltration.

We found that silencing CENPA significantly increased reactive oxygen species production and mitochondrial membrane potential abnormalities leading to inhibition of cell viability and proliferation and cell death, suggesting that CENPA is closely associated with the development of KIRC. In conclusion, IGF2BP3 and its downstream CENPA signature can be used for prognostic prediction of KIRC.